Operative Unity of Neurology, Siracusa, Italy.
Minerva Med. 2011 Apr;102(2):141-7.
Carpal tunnel syndrome (CTS) is a medical condition in which the median nerve is compressed, leading to discomfort and pain. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, able to modulate inflammatory cell reactivity and pain. This study deals with the capability of PEA to normalize the electroneurographic alterations associated with moderate CTS.
Patients displaying moderate CTS were enrolled and daily PEA (600 mg or 1 200 mg/die) was administered for 30 days. Control group received no treatment.
PEA treatment significantly improved the CTS-induced reduction of median nerve latency time (P<0.0004); PEA effect was dose-dependent. Tinel's sign presence and symptoms of discomfort were also reduced.
Although further studies are needed to better characterize PEA effect, the present report represents the first evidence on the improvement of distal motor latency elicited by PEA in patients with moderate CTS. The data support the hypothesis of protection against inflammatory and neuropathic pain by PEA.
腕管综合征（CTS）是一种正中神经受压的疾病，会导致不适和疼痛。棕榈酰乙醇酰胺（PEA）是一种内源性脂肪酸酰胺，能够调节炎症细胞的反应性和疼痛。本研究旨在探讨 PEA 使中度 CTS 相关的电神经图改变正常化的能力。
纳入患有中度 CTS 的患者，并每天给予 PEA（600mg 或 1200mg/die）治疗 30 天。对照组未接受治疗。
PEA 治疗可显著改善 CTS 引起的正中神经潜伏期时间的减少（P<0.0004）；PEA 的作用呈剂量依赖性。Tinel 征的出现和不适症状也减少。
尽管需要进一步研究来更好地描述 PEA 的作用，但本报告首次提供了 PEA 改善中度 CTS 患者诱发的运动神经潜伏期的证据。这些数据支持 PEA 对炎症和神经病理性疼痛的保护作用假说。
